Efficacy of Filgotinib in Moderate to Severe Ulcerative Colitis: A Prospective Study Using Partial Mayo Score, Ulcerative Colitis Endoscopic Index of Severity, and Geboes Histopathology Score.

• Tác giả: Yasumi Araki, Tomoko Irie, Hideki Ishibashi, Masayoshi Kage, Yutaro Mihara, Keiichi Mitsuyama, Kazuyoshi Nagata, Toshihiro Noake, Toshihiro Ohmiya, Yuka Sakakibara, Yoshiyuki Shirouzu, Asami Suzuki, Hidetoshi Takedatsu
• Ngôn ngữ: eng
• Ký hiệu phân loại: 333.822 Coal
• Thông tin xuất bản: England : Crohn's & colitis 360 , 2025
• Bộ sưu tập: NCBI
• ID: 748613
• Chủ đề: 1. Efficacy; 2. Of; 3. Filgotinib

Tóm tắt

 BACKGROUND/AIMS: Filgotinib (FIL), a Janus kinase inhibitor, shows clinical efficacy in moderate to severe ulcerative colitis (UC), but no prospective studies have examined endoscopic and histopathological outcomes. This study aimed to evaluate the therapeutic efficacy of FIL in moderate to severe UC using the Partial Mayo Score (PMS), Ulcerative Colitis Endoscopic Index of Severity (UCEIS), and Geboes Histopathology Score (GHS). METHODS: Twenty-two patients with clinically moderate to severe refractory UC were enrolled. Remission was defined as PMS 0, UCEIS 0, and GHS <
  2.0 (sigmoid and rectum). Achievement rates were prospectively evaluated at 12, 24, and 52 weeks after FIL initiation compared to baseline. RESULTS: Among the 22 patients, comprising Biologic-Naïve (BN, CONCLUSIONS: Filgotinib appears to be an effective treatment for UC, demonstrating potential for achieving not only clinical remission but also endoscopic and histopathological remission.